rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Using GEM models, we tested whether PI3'-lipid signaling was limiting for the promotion of KRAS(G12D)-driven lung tumors by inducing the expression of KRAS(G12D) in the absence and presence of the activating PIK3CA(H1047R) mutation.
|
26567140 |
2015 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids.
|
25077772 |
2014 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.
|
23959381 |
2013 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo.
|
21994468 |
2011 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Moreover, Klf5 is not required for lung tumor formation in an inducible oncogenic K-Ras(G12D) mouse model of lung tumorigenesis, and non-small cell lung cancer patients expressing high levels of KLF5 (21/258) have a significantly better disease-specific survival than those with intermediate to no KLF5 expression.
|
20639455 |
2010 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Importantly, the combined inactivation of both MYC and K-ras(G12D) resulted more frequently in complete lung tumor regression.
|
18461184 |
2008 |
rs121913530
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We find no evidence of heterogeneity that may compromise KRAS G12C targeted therapy within sequenced lung tumors or passaged xenografts.
|
29453361 |
2018 |